相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Identification of MicroRNAs as Diagnostic Biomarkers for Breast Cancer Based on the Cancer Genome Atlas
Jungho Kim
DIAGNOSTICS (2021)
Mechanistic insights of adipocyte metabolism in regulating breast cancer progression
Fuchuang Zhang et al.
PHARMACOLOGICAL RESEARCH (2020)
Non-invasive early detection of cancer four years before conventional diagnosis using a blood test
Xingdong Chen et al.
NATURE COMMUNICATIONS (2020)
Application of metabolomics in the diagnosis of breast cancer: a systematic review
Liqing Yang et al.
JOURNAL OF CANCER (2020)
Adipose-derived stem cells enhance human breast cancer growth and cancer stem cell-like properties through adipsin
Hideaki Goto et al.
ONCOGENE (2019)
Mastocheck: Notable plasma protein biomarker for diagnosis of breast cancer in the real clinical practice by using multiple reaction monitoring-based mass spectrometry.
Yumi Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification
L. Liu et al.
ANNALS OF ONCOLOGY (2018)
The future of blood-based biomarkers for the early detection of breast cancer
Sau Yeen Loke et al.
EUROPEAN JOURNAL OF CANCER (2018)
Is liquid biopsy ready for the litmus test and what has been achieved so far to deal with pre-analytical issues?
Bernd Schmidt et al.
TRANSLATIONAL CANCER RESEARCH (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Epigenetic regulation of ID4 in breast cancer: tumor suppressor or oncogene?
Daniela Nasif et al.
CLINICAL EPIGENETICS (2018)
A DNA Methylation-Based Test for Breast Cancer Detection in Circulating Cell-Free DNA
Sofia Salta et al.
JOURNAL OF CLINICAL MEDICINE (2018)
Factors that influence quality and yield of circulating-free DNA: A systematic review of the methodology literature
R. M. Trigg et al.
HELIYON (2018)
Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size
Zahra Malek-Hosseini et al.
BREAST CANCER (2017)
Value of the level of methylation of RASSF1A and WIF-1 in tissue and serum in neoadjuvant chemotherapeutic assessment for advanced breast cancer
Zhong-Hua Han et al.
ONCOLOGY LETTERS (2017)
Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping
Xiaofeng Dai et al.
JOURNAL OF CANCER (2017)
Methylation of DACT2 promotes breast cancer development by activating Wnt signaling
Jingyi Li et al.
SCIENTIFIC REPORTS (2017)
The role of IL17B-IL17RB signaling pathway in breast cancer
Vahideh Alinejad et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples
Anna Kazarian et al.
BRITISH JOURNAL OF CANCER (2017)
Identification of a panel of complex autoantigens (LGALS3, PHB2, MUC1, and GK2) in combination with CA15-3 for the diagnosis of early-stage breast cancer
Xiaoxiao Zuo et al.
TUMOR BIOLOGY (2016)
Low expression of leptin and its association with breast cancer: A transcriptomic study
Sajjad Karim et al.
ONCOLOGY REPORTS (2016)
Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer
Ming Shan et al.
ONCOTARGET (2016)
DACT2 silencing by promoter CpG methylation disrupts its regulation of epithelial-to-mesenchymal transition and cytoskeleton reorganization in breast cancer cells
Tingxiu Xiang et al.
ONCOTARGET (2016)
Blood-based DNA methylation as biomarker for breast cancer: a systematic review
Qiuqiong Tang et al.
CLINICAL EPIGENETICS (2016)
Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer
Dorit Di Gioia et al.
CLINICA CHIMICA ACTA (2015)
CDKN2A (p14ARF/p16INK4a) and ATM promoter methylation in patients with impalpable breast lesions
Lucas Delmonico et al.
HUMAN PATHOLOGY (2015)
Estrogen receptor alpha (ERα) promoter methylation status in tumor and serum DNA in Egyptian breast cancer patients
Hoda A. Hagrass et al.
GENE (2014)
THE SIGNIFICANCE OF CA15-3 IN BREAST CANCER PATIENTS AND ITS RELATIONSHIP TO HER-2 RECEPTOR STATUS
Z. M. Hashim
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2014)
E4BP4 is a repressor of epigenetically regulated SOSTDC1 expression in breast cancer cells
Akhilesh Rawat et al.
CELLULAR ONCOLOGY (2014)
SOX10, a novel HMG-box-containing tumor suppressor, inhibits growth and metastasis of digestive cancers by suppressing the Wnt/β-catenin pathway
Xin Tong et al.
ONCOTARGET (2014)
Associations with growth factor genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: the Breast Cancer Health Disparities Study
Martha L. Slattery et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer
Ann Christina Pedersen et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2013)
SOSTDC1 down-regulation of expression involves CpG methylation and is a potential prognostic marker in gastric cancer
Gopisetty Gopal et al.
CANCER GENETICS (2013)
Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening
Vera Kloten et al.
BREAST CANCER RESEARCH (2013)
Comparison of Stain-Free gels with traditional immunoblot loading control methodology
Alex D. Colella et al.
ANALYTICAL BIOCHEMISTRY (2012)
BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls
Remy Bosviel et al.
CANCER EPIDEMIOLOGY (2012)
High levels of DJ-1 protein in nipple fluid of patients with breast cancer
Miki Oda et al.
CANCER SCIENCE (2012)
A Bead-Based Multiplexed Immunoassay to Evaluate Breast Cancer Biomarkers for Early Detection in Pre-Diagnostic Serum
Annemieke W. J. Opstal-van Winden et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer
Kathryn A. Clausen et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Hypermethylation of Tumor Suppressor Genes Involved in Critical Regulatory Pathways for Developing a Blood-Based Test in Breast Cancer
Ramin Radpour et al.
PLOS ONE (2011)
Identification and validation of genes involved in gastric tumorigenesis
Thangarajan Rajkumar et al.
CANCER CELL INTERNATIONAL (2010)
Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer
Juergen Veeck et al.
BMC CANCER (2009)
How effective are breast cancer screening programmes by mammography? Review of the current evidence
Doris Schopper et al.
EUROPEAN JOURNAL OF CANCER (2009)
Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients
James M. Flanagan et al.
HUMAN MOLECULAR GENETICS (2009)
Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer
H. Suzuki et al.
BRITISH JOURNAL OF CANCER (2008)
Leptin Signaling in Breast Cancer: An Overview
Donatella Cirillo et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2008)
Mining the plasma proteome for cancer biomarkers
Samir M. Hanash et al.
NATURE (2008)
Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer
Lingbao Ai et al.
CARCINOGENESIS (2006)
Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation
T. E. Skvortsova et al.
BRITISH JOURNAL OF CANCER (2006)
WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer
C Wissmann et al.
JOURNAL OF PATHOLOGY (2003)
High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis
M Barbareschi et al.
CANCER (2003)
The insulin-like growth factor system and cancer
D LeRoith et al.
CANCER LETTERS (2003)
Long-term follow-up and prognostic significance of angiogenic basic fibroblast growth factor (bFGF) expression in patients with breast cancer
A Faridi et al.
PATHOLOGY RESEARCH AND PRACTICE (2002)
Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer
R D'Alessandro et al.
BREAST CANCER RESEARCH AND TREATMENT (2001)